TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25808818

Group type: COMPARATOR
Intervention: Favipiravir (acute administration for 1 day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Favipiravir (extended administration for 6 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Favipiravir co-administration
Number of subjects: 0
Study: 23845297

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivatives (EMD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bio‐Oss Collagen
Number of subjects: 20
Study: 20501622

Group type: EXPERIMENTAL
Intervention: Rapamycin 3 mg
Number of subjects: 32
Study: 18707820

Group type: EXPERIMENTAL
Intervention: Weekly carboplatin (area under the curve of 2) during RT
Number of subjects: 18

Group type: COMPARATOR
Intervention: Carboplatin and etoposide every 3 weeks during RT (Trans‐Tasman Radiation Oncology Group 96:07 study)
Number of subjects: 18
Study: 16517502

Group type: EXPERIMENTAL
Intervention: 500 mg of DHA and 150 mg of EPA
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (without DHA and EPA)
Number of subjects: 46
Study: 12640214

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 10813579

Group type: EXPERIMENTAL
Intervention: Small for gestational age (SGA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Appropriate for gestational age (AGA)
Number of subjects: 36
Study: 8800165

Group type: EXPERIMENTAL
Intervention: Early extubation group (n = 60; 15 micrograms.kg‐1 fentanyl and 2 to 6 mg.kg‐1.hour‐1 propofol and isoflurane)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional extubation group (n = 60; 50 micrograms.kg‐1 fentanyl and 0.1 mg.kg‐1 midazolam and isoflurane)
Number of subjects: 120
Study: 1386224

Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sufentanil 50 micrograms
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Morphine 2 mg with Sufentanil 25 micrograms
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 64
Study: 6365351

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n = 19)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Muscle relaxation and low-level exercise (n = 9)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 31409559

Group type: EXPERIMENTAL
Intervention: Exergame training
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 115

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 115
Study: 29497063

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both groups (Simvastatin and Placebo)
Number of subjects: 118
Study: 27411172

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) and arachidonic acid (AA) levels in the umbilical cord
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: AA:DHA ratio in the umbilical vein
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Neonatal LCPUFA status
Number of subjects: 229
Study: 23632408

Group type: EXPERIMENTAL
Intervention: Cotton swabs soaked in 4% lidocaine applied to the globe with moderate pressure
Number of subjects: 48

Group type: COMPARATOR
Intervention: 3.5% lidocaine gel applied without pressure
Number of subjects: 48
Study: 22094937

Group type: COMPARATOR
Intervention: Epirubicin (75 mg/m²) + Paclitaxel (175 mg/m²)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m²) + Paclitaxel (155 mg/m²) + Capecitabine (825 mg/m² BID for 14 days)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group (ET)
Number of subjects: 287
Study: 19016569

Group type: COMPARATOR
Intervention: 20-mL syringe with vacuum obtained by a hand-grip device (Group 1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 4-mL Vacutainer connected to the needle (Group 2)
Number of subjects: 200
Study: 17451416

Group type: EXPERIMENTAL
Intervention: Brushing
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Brushing + Flossing
Number of subjects: 34

Group type: COMPARATOR
Intervention: Direct measure of IPP (plaque weight)
Number of subjects: 34
Study: 15281697

Group type: EXPERIMENTAL
Intervention: Six-week psychoeducational group intervention
Number of subjects: 27
Study: 12452872

Group type: EXPERIMENTAL
Intervention: UVA irradiation (cumulative doses of 96 J cm‐2 for skin type II and 126 J cm‐2 for skin type III)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-exposed (control group)
Number of subjects: 44
Study: 9520071

Group type: EXPERIMENTAL
Intervention: Elevated IgM anti‐GM1 levels in patients with neuropathies (NP)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Median levels of IgM‐, IgG‐, (IgM+IgG)‐, and C5b‐9‐binding anti‐GM1
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Median levels of IgG‐ and (IgM+IgG)‐anti‐GM1
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Complement‐binding activity
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Anti‐GM1 level (IgM+IgG)
Number of subjects: 243
Study: 8129608

Group type: EXPERIMENTAL
Intervention: Preoperative, noninvasive: The redox tolerance test (RTT) measuring changes in arterial ketone body ratio in response to 75 g of oral glucose loading.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraoperative, invasive: Cytochrome c oxidase activity and energy charge of the liver.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group B (RTI < 0.5)
Number of subjects: 40
Study: 2679237

Group type: EXPERIMENTAL
Intervention: 6.25 micrograms fentanyl
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 56
Study: 31645305

Group type: EXPERIMENTAL
Intervention: Low titer group O whole blood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood components therapy
Number of subjects: 0
Study: 29019364

Group type: EXPERIMENTAL
Intervention: Blueberry treatment (BB; 300 g of blueberry)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control treatment (C; 300 mL of water with sugar)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Blueberry treatment with smoking (BS; 300 g of blueberry + smoking)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control treatment with smoking (CS; 300 mL of water with sugar + smoking)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Smoking treatment (S)
Number of subjects: 24
Study: 23897051

Group type: EXPERIMENTAL
Intervention: Transposterior arch lateral mass screw fixation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Lateral mass screw fixation
Number of subjects: 66
Study: 23456557

Group type: EXPERIMENTAL
Intervention: Physical activity (self-report and objective measures)
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Physical activity (accelerometer data subsample)
Number of subjects: 1527
Study: 21332563

Group type: EXPERIMENTAL
Intervention: Off-pump surgery (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: On-pump surgery (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preoperative nitroglycerine use
Number of subjects: 40
Study: 19826306

Group type: EXPERIMENTAL
Intervention: Commercially formulated water
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bottled water (placebo)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte beverage (6% or 60 g L(‐1))
Number of subjects: 21
Study: 17082474

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF) 10 microg/kg for 5 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15554360

Group type: EXPERIMENTAL
Intervention: 4G/4G genotype
Number of subjects: 547

Group type: COMPARATOR
Intervention: 4G/5G genotype
Number of subjects: 547

Group type: COMPARATOR
Intervention: 5G/5G genotype
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: PAI-1 plasma levels
Number of subjects: 547
Study: 11297210

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (10(6) KIU after induction of anesthesia and 10(6) KIU in pump prime)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 36
Study: 9226484

Group type: EXPERIMENTAL
Intervention: 20 g of water soluble fibre (guar gum) daily for 14 months
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fibre consuming group with 50-80% compliance (group B)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fibre supplementation
Number of subjects: 31
Study: 8213300

Group type: EXPERIMENTAL
Intervention: Incentive program
Number of subjects: 1100

Group type: COMPARATOR
Intervention: No Incentive
Number of subjects: 1100
Study: 2888185

Group type: EXPERIMENTAL
Intervention: 75 mg HOE 760
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28084834

Group type: COMPARATOR
Intervention: Progressive Neck Exercise Program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive Behavioral Modification Therapy
Number of subjects: 0
Study: 27480314

Group type: EXPERIMENTAL
Intervention: Protocolized sedation with daily sedation interruption
Number of subjects: 423

Group type: COMPARATOR
Intervention: Protocolized sedation alone
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Nighttime sedation
Number of subjects: 423

Group type: COMPARATOR
Intervention: Daytime sedation
Number of subjects: 423
Study: 25527842

Group type: EXPERIMENTAL
Intervention: Corticosteroid and local anaesthetic injections administered by a physiotherapist
Number of subjects: 64

Group type: COMPARATOR
Intervention: Corticosteroid and local anaesthetic injections administered by an orthopaedic surgeon
Number of subjects: 64
Study: 22898679

Group type: EXPERIMENTAL
Intervention: Imatinib with chemotherapy (good-risk group)
Number of subjects: 178

Group type: COMPARATOR
Intervention: No imatinib with chemotherapy (good-risk group)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Imatinib with chemotherapy (as-treated analysis, good-risk group)
Number of subjects: 178

Group type: COMPARATOR
Intervention: No imatinib with chemotherapy (as-treated analysis, good-risk group)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Imatinib with chemotherapy (poor-risk group)
Number of subjects: 178
Study: 20384990

Group type: EXPERIMENTAL
Intervention: Treatment according to clinical practice guidelines (CPGs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treatment or treatment not according to CPGs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incidence of sarcoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survival rate
Number of subjects: 0
Study: 18362489

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no finasteride)
Number of subjects: 30
Study: 16120545

Group type: EXPERIMENTAL
Intervention: Tumor vascularity assessed by Chalkley counting (TVC) in prostate core biopsies
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (patients without PSA recurrence)
Number of subjects: 50
Study: 12163992

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiation with cisplatin 40 mg/m2 weekly for 6 courses and HDR brachytherapy (7 Gy in point A per fraction, total dose 35 Gy)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 27
Study: 10195522

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPS) pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no MPS pretreatment)
Number of subjects: 0
Study: 7486115

Group type: EXPERIMENTAL
Intervention: Propofol blood concentration 1 microgram/mL
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propofol blood concentration 2 micrograms/mL
Number of subjects: 14

Group type: COMPARATOR
Intervention: No propofol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propofol blood concentration
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bispectral Index
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 95% spectral edge frequency
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bispectral Index vs. propofol concentration
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 95% spectral edge frequency vs. propofol concentration
Number of subjects: 14
Study: 2403089

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Children's Coma Score
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Children's Orthopedic Hospital and Medical Center Scale
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0 to IV Scale
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Simpson and Reilly Scale
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Jacobi Scale
Number of subjects: 15
Study: 6769773

Group type: COMPARATOR
Intervention: Oral thioctic acid for 21 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous thioctic acid for 21 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 20
Study: 30999123

Group type: EXPERIMENTAL
Intervention: Ignore condition
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Challenge condition
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Reassured condition
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Reciprocated condition
Number of subjects: 191
Study: 29068995

Group type: EXPERIMENTAL
Intervention: PASAT distraction during chest compressions
Number of subjects: 44

Group type: COMPARATOR
Intervention: No PASAT distraction during chest compressions
Number of subjects: 44
Study: 25403264

Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (POM+LoDEX)
Number of subjects: 455

Group type: COMPARATOR
Intervention: High-dose dexamethasone (HiDEX)
Number of subjects: 455
Study: 24687833

Group type: EXPERIMENTAL
Intervention: Panitumumab plus mFOLFOX6
Number of subjects: 285

Group type: COMPARATOR
Intervention: Bevacizumab plus mFOLFOX6
Number of subjects: 285
Study: 23095185

Group type: EXPERIMENTAL
Intervention: DHA group (200 mg/day DHA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (pooled controls)
Number of subjects: 120
Study: 19544822

Group type: EXPERIMENTAL
Intervention: KTP laser + Clearfil SE Bond
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate + Clearfil SE Bond
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clearfil SE Bond
Number of subjects: 30
Study: 17634485

Group type: EXPERIMENTAL
Intervention: Nolatrexed (NOL)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Doxorubicin (DOX)
Number of subjects: 445
Study: 16436239

Group type: EXPERIMENTAL
Intervention: Méniètt device (local overpressure treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 0
Study: 14761073

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8‐12 mg once a day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dihydropyridine calcium-channel blockers (DCCBs)
Number of subjects: 100
Study: 10872643

Group type: EXPERIMENTAL
Intervention: tolcapone 50 mg
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: tolcapone 200 mg
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: tolcapone 400 mg
Number of subjects: 412

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: tolcapone (various doses)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: tolcapone
Number of subjects: 412
Study: 9031808

Group type: EXPERIMENTAL
Intervention: PDPD patients
Number of subjects: 110

Group type: COMPARATOR
Intervention: Type 1 diabetes patients
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: PDPD patients at onset
Number of subjects: 110

Group type: COMPARATOR
Intervention: FCPD patients
Number of subjects: 110
Study: 1984381

Group type: EXPERIMENTAL
Intervention: 2 mg morphine
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 4 mg morphine
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: All groups (2 mg, 4 mg, placebo)
Number of subjects: 154
Study: 6138061

Group type: EXPERIMENTAL
Intervention: 20 mg of midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg of midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg of midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 mg of flurazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31189985

Group type: EXPERIMENTAL
Intervention: High definition TACS
Number of subjects: 60

Group type: COMPARATOR
Intervention: High definition TDCS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study: 29863387

Group type: EXPERIMENTAL
Intervention: 12 mg of tiagabine/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0 mg of tiagabine/day (placebo)
Number of subjects: 12
Study: 27053573

Group type: EXPERIMENTAL
Intervention: Dietetic weight loss intervention (at least four sessions with an Accredited Practising Dietitian)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dietetic weight loss intervention
Number of subjects: 40
Study: 24665641

Group type: EXPERIMENTAL
Intervention: Simultaneous operation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Staging operation
Number of subjects: 50
Study: 22299805

Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM) intervention contingent on submitting negative urine drug screens (UDS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Noncontingent control group
Number of subjects: 31
Study: 19185539

Group type: EXPERIMENTAL
Intervention: Pregabalin (exact dosage and duration not specified)
Number of subjects: 1493
Study: 17397610

Group type: EXPERIMENTAL
Intervention: Sodium heparin 100 IU (study 1)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Sodium heparin 500 IU (control 1)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Saline solution (SS) (study 2)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Sodium heparin 100 IU (control 2)
Number of subjects: 223
Study: 15792677

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 30

Group type: COMPARATOR
Intervention: none (control)
Number of subjects: 30
Study: 12147166

Group type: EXPERIMENTAL
Intervention: 0.025% NaF mouthrinse for 2 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% NaF mouthrinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no fluoride program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NaF content reduction
Number of subjects: 0
Study: 10519944

Group type: EXPERIMENTAL
Intervention: 20 microg of MSP-1(19) vaccine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 200 microg of MSP-1(19) vaccine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control vaccines (hepatitis B or Td)
Number of subjects: 16
Study: 8573550

Group type: EXPERIMENTAL
Intervention: Pravastatin (PRAV)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lovastatin (LOV)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cholestyramine (CHOL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2209838

Group type: EXPERIMENTAL
Intervention: Early second surgery after three cycles of cis-platinum-based chemotherapy (median of 14 weeks from initial laparotomy)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (historical series of patients with residual disease receiving cis-platinum but no early secondary surgery)
Number of subjects: 24
Study: 7202896

Group type: EXPERIMENTAL
Intervention: metoprolol up to 200 mg bid
Number of subjects: 119

Group type: COMPARATOR
Intervention: methyldopa up to 500 mg bid
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: metoprolol alone after methyldopa
Number of subjects: 119
Study: 31740343

Group type: EXPERIMENTAL
Intervention: Ibandronate (150 mg/month)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg/week)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg/week)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D (daily)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (226 healthy premenopausal women receiving no treatments)
Number of subjects: 165
Study: 31310626

Group type: EXPERIMENTAL
Intervention: Single-session pattern scanning laser (Pascal)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional multiple-session laser
Number of subjects: 30
Study: 27611235

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Enhanced (CBT-E)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Integrative Cognitive-Affective Therapy for BN (ICAT-BN)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Personality subtype
Number of subjects: 80
Study: 23963625

Group type: EXPERIMENTAL
Intervention: school-based nutrition and physical activity curriculum
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: across-the-lifespan train-the-trainer program
Number of subjects: 600
Study: 23565841

Group type: EXPERIMENTAL
Intervention: High-flavanol chocolate (40g dose)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low-flavanol chocolate (40g dose)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-flavanol chocolate (20g daily intake for 12 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low-flavanol chocolate (20g daily intake for 12 weeks)
Number of subjects: 44
Study: 21150222

Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment
Number of subjects: 8963

Group type: EXPERIMENTAL
Intervention: Incident patients
Number of subjects: 8963

Group type: EXPERIMENTAL
Intervention: Prevalent patients
Number of subjects: 8963

Group type: EXPERIMENTAL
Intervention: Medication use
Number of subjects: 8963

Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 8963
Study: 19208728

Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SSA) treatment
Number of subjects: 31
Study: 17854530

Group type: EXPERIMENTAL
Intervention: Removal of cervical mucus prior to embryo transfer
Number of subjects: 317

Group type: COMPARATOR
Intervention: Mock procedure (control)
Number of subjects: 317